Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Young

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
Advances in Skin & Wound Care|September 16, 2025
A Composite Dermal Matrix Comprising Ovine Forestomach Matrix and Hyaluronic Acid in the Treatment of Chronic Wounds Secondary to Calciphylaxis: A Case Series and Literature ReviewLai Le, Leticia Ribeiro Silva, Brandon A Bosque, et al.
Rheumatology (Oxford, England)|March 8, 2021
The use and context of the term 'multimorbidity' in rheumatoid arthritis: a systematic literature reviewMrinalini Dey, Amanda Busby, Helen Elwell, et al.
Rheumatology (Oxford, England)|July 24, 2021
Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?Amanda D Busby, James Wason, Arthur G Pratt, et al.
Rheumatology International|October 29, 2018
Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28Lewis Carpenter, Sam Norton, Elena Nikiphorou, et al.
Arthritis Care & Research|August 27, 2016
Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory StatesElena Nikiphorou, Sam Norton, Lewis Carpenter, et al.
Rheumatology (Oxford, England)|January 4, 2020
Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritisLewis Carpenter, Elena Nikiphorou, Patrick D W Kiely, et al.
Pharmacoeconomics|March 5, 2018
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalShijie Ren, Iñigo Bermejo, Emma Simpson, et al.
Pharmacoeconomics|June 9, 2018
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalIñigo Bermejo, Shijie Ren, Emma Simpson, et al.
Rheumatology (Oxford, England)|March 8, 2022
The role of comorbidities alongside patient and disease characteristics in long-term disease activity in RA using UK inception cohort dataAmanda D Busby, James Wason, Arthur G Pratt, et al.
Annals of the Rheumatic Diseases|March 17, 2016
Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholdsElena Nikiphorou, Sam Norton, Adam Young, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Advances in Skin & Wound Care|September 16, 2025
A Composite Dermal Matrix Comprising Ovine Forestomach Matrix and Hyaluronic Acid in the Treatment of Chronic Wounds Secondary to Calciphylaxis: A Case Series and Literature ReviewLai Le, Leticia Ribeiro Silva, Brandon A Bosque, et al.
Rheumatology (Oxford, England)|March 8, 2021
The use and context of the term 'multimorbidity' in rheumatoid arthritis: a systematic literature reviewMrinalini Dey, Amanda Busby, Helen Elwell, et al.
Rheumatology (Oxford, England)|July 24, 2021
Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?Amanda D Busby, James Wason, Arthur G Pratt, et al.
Rheumatology International|October 29, 2018
Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28Lewis Carpenter, Sam Norton, Elena Nikiphorou, et al.
Arthritis Care & Research|August 27, 2016
Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory StatesElena Nikiphorou, Sam Norton, Lewis Carpenter, et al.
Rheumatology (Oxford, England)|January 4, 2020
Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritisLewis Carpenter, Elena Nikiphorou, Patrick D W Kiely, et al.
Pharmacoeconomics|March 5, 2018
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalShijie Ren, Iñigo Bermejo, Emma Simpson, et al.
Pharmacoeconomics|June 9, 2018
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalIñigo Bermejo, Shijie Ren, Emma Simpson, et al.
Rheumatology (Oxford, England)|March 8, 2022
The role of comorbidities alongside patient and disease characteristics in long-term disease activity in RA using UK inception cohort dataAmanda D Busby, James Wason, Arthur G Pratt, et al.
Annals of the Rheumatic Diseases|March 17, 2016
Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholdsElena Nikiphorou, Sam Norton, Adam Young, et al.
Pageof 12